Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay)

被引：2
|
作者：
Hou, Yanjun [1 ]
Tozbikian, Gary [1 ]
Zynger, Debra L. [1 ]
Li, Zaibo [1 ]
机构：
[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave, Columbus, OH 43210 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2017年 / 147卷 / 06期
关键词：
Breast cancer; Estrogen receptor; Magee equation; Oncotype DX; Recurrence score; INVASIVE BREAST-CANCER; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PRIMARY TUMOR; PREDICT; PROGNOSIS; EXPRESSION; DECISIONS; PATHOLOGY; THERAPY;
D O I：
10.1093/AJCP/AQX008
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX. Methods: Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS. Results: The Pearson correlation coefficient (r) for the Magee equation and Oncotype DX RS was 0.6645 (P<.00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively. Conclusions: The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.
引用
收藏
页码：541 / 548
页数：8
相关论文
共 50 条
  • [41] Use of the Oncotype DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer
    Alison K. Conlin
    Andrew D. Seidman
    Molecular Diagnosis & Therapy, 2007, 11 : 355 - 360
  • [42] Use of the Oncotype DX™ 21-gene assay to guide adjuvant decision making in early-stage breast cancer
    Conlin, Alison K.
    Seidman, Andrew D.
    MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (06) : 355 - 360
  • [43] Budget impact analysis of the 21-gene assay (Oncotype DX® breast cancer) for the breast cancer treatment in the Basque country
    Toribio, M. G.
    Mar, J.
    Galve, E.
    Alvarez, I.
    Lahuerta, A.
    Unanue, G.
    Ibarrondo, O.
    Novas, P.
    Ancizar, N.
    Larburu, L.
    Hidalgo, M.
    Arango, J. F.
    Churruca, C.
    Plazaola, A.
    Perez, I.
    Purificacion Martinez del Prado, P.
    Dominguez, S.
    Paisan, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Practice-changing use of the 21-gene oncotype DX breast recurrence score test in Latin American hospitals.
    Leonidas Gomez, Henry
    Enrique Bargallo-Rocha, Juan
    Jorge Billinghurst, Roberto
    Nunez de Pierro, Anibal Roberto
    Andres Colo, Federico
    Benitez Gil, Lisandro Luis
    Allemand, Carola
    Leonardo McLean, Ignacio
    Lema-Medina, Mauricio
    Herazo-Maya, Fernando
    Jose Terrier, Francisco
    Gerson Cwilich, Raquel
    Leon Rivera, Mauricio
    Gabriela Falcon, Silvia
    Eduardo Castano, Roberto
    Cordeiro Oliveira, Sergio
    Jakubowski, Debbie M.
    Chao, Calvin Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: Experience of Kuwait Cancer Control Center.
    Fayaz, Mohamed Salah
    Eissa, Heba
    Demian, Gerges Attia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Comparison of the 21-Gene Recurrence Score Assay in Women and Men with Early Stage Breast Cancer
    Allen, A.
    Kwon, D.
    Avisar, E.
    Goel, N.
    Kesmodel, S. B.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S102 - S102
  • [47] Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer
    Woodward, Wendy A.
    Barlow, William E.
    Jagsi, Reshma
    Buchholz, Thomas A.
    Shak, Steven
    Baehner, Frederick
    Whelan, Timothy J.
    Davidson, Nancy E.
    Ingle, James N.
    King, Tari A.
    Ravdin, Peter M.
    Osborne, C. Kent
    Tripathy, Debasish
    Livingston, Robert B.
    Gralow, Julie R.
    Hortobagyi, Gabriel N.
    Hayes, Daniel F.
    Albain, Kathy S.
    JAMA ONCOLOGY, 2020, 6 (04) : 505 - 511
  • [48] A COST-CONSEQUENCE MODEL OF USING THE 21-GENE BREAST RECURRENCE SCORE ASSAY TO IDENTIFY PATIENTS WITH EARLY-STAGE NODE-POSITIVE BREAST CANCER WHO BENEFIT FROM ADJUVANT CHEMOTHERAPY IN THE NETHERLANDS
    Machielsen, P.
    de Jongh, F. E.
    Drost, P.
    Simons, M.
    Spoorendonk, J. A.
    VALUE IN HEALTH, 2022, 25 (12) : S63 - S63
  • [49] Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
    Ridolfi, Kimberly
    Zhang, Chong
    Onitilo, Adedayo A.
    Ledesma, Wendy M.
    Andreason, Molly
    Engel, Jessica Marie
    Kim, KyungMann
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Charlson, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
    Turashvili, Gulisa
    Wen, Hannah Y.
    BREAST JOURNAL, 2020, 26 (06): : 1199 - 1207
12345